Copyright
©The Author(s) 2020.
World J Gastrointest Pharmacol Ther. Jun 9, 2020; 11(2): 17-24
Published online Jun 9, 2020. doi: 10.4292/wjgpt.v11.i2.17
Published online Jun 9, 2020. doi: 10.4292/wjgpt.v11.i2.17
Table 1 Acromegaly demographic and treatment data
Controls | Acromegaly patients | |
n | 200 | 50 |
M:F | 96:104 | 24:26 |
Age at diagnosis (mean, yr) | 33 | 32.44 |
Years since diagnosis (mean, yr) | - | 11.8 yr |
Transsphenoidal surgery | - | 50 (100%) |
Pituitary radiotherapy | - | 21 (42%) |
Somatostatin analogue | - | 37 (74%) |
Table 2 Acromegaly abdominal symptoms and medicine use
Controls (n = 200) | Acromegaly patients (n = 50) | P value (Fisher’s exact test) | ||
Gastrointestinal symptoms | 32 (16%) | 46 (92%) | ||
Abdominal pain | 19 (9.5%) | 11(22%) | 0.4905 | |
Diarrhoea | 8 (4%) | 4 (8%) | 0.2652 | |
Constipation | 15 (7.5%) | 34 (68%) | < 0.00001b | |
Medicines | ||||
Regular use of anti-secretory (PPI/H2RA)/antacids | 11 (6.5%) | 31 (62%) | < 0.00001b | |
Regular use of laxatives | 6 (3%) | 46 (92%) | < 0.00001b | |
Regular use of opioid analgesics | 11 (6.5%) | 2 (4%) | Not statistically significant | |
Somatostatin analogues | - | 37 (74%) |
Table 3 Gastrointestinal symptoms in acromegaly patients compared with controls
Controls, n = 200 (%) | Acromegaly patients, n = 50 (%) | P value (Fisher’s exact test) | ||
Oesophageal disorders | ||||
Functional chest pain | 2 (1%) | 3 (6%) | 0.0561 | |
Functional heartburn | 22 (11%) | 15 (30%) | 0.0016b | |
Globus | 2 (1%) | 2 (4%) | 0.1796 | |
Functional dysphagia | 4 (2%) | 6 (12%) | 0.0053b | |
Gastroduodenal disorders | ||||
Functional dyspepsia | 14 (7%) | 12 (24%) | 0.0013b | |
Belching disorders | 8 (4%) | 5 (10%) | 0.1441 | |
Nausea and vomiting disorders | 2 (1%) | 2 (4%) | 0.1796 | |
Rumination syndrome | 2 (1%) | 1 (2%) | 0.4895 | |
Bowel disorders | ||||
Irritable bowel syndrome | 12 (6%) | 10 (20%) | 0.0041b | |
Functional constipation | 22 (11%) | 34 (68%) | 0.0006b | |
Functional diarrhoea | 10 (5%) | 9 (18%) | 0.0048b | |
Functional abdominal bloating/distension | 12 (6%) | 11 (22%) | 0.0015b | |
Unspecified functional bowel disorder | 44 (22%) | 25 (50%) | 0.0002b | |
Centrally mediated Abdominal pain syndrome | 6 (3%) | 4 (8%) | 0.1165 | |
Functional Biliary pain | 1 (0.5%) | 3 (6%) | 0.0261a | |
Anorectal disorders | ||||
Faecal incontinence | 1 (0.5%) | 2 (4%) | 0.1028 | |
Functional anorectal pain | 2 (1%) | 4 (8%) | 0.0157a |
Table 4 Quality of life scores in acromegaly patients
Controls (mean scores) | Acromegaly (mean scores) | Independent sample t test | |
Physical functioning | 100.0 | 80.0 | 0.80516 |
Role limitations due to physical health | 100.0 | 50.0 | 0.001053b |
Role limitations due to emotional problems | 100.0 | 100.0 | 1 |
Level of energy/fatigue | 95.0 | 45.0 | 0.001053b |
Emotional wellbeing | 100.0 | 68.0 | 0.002175b |
Social functioning | 87.5 | 50.0 | < 0.000076b |
Pain | 77.5 | 67.5 | 0.1732 |
General health | 100 | 30.0 | < 0.0001b |
- Citation: Inayet N, Hayat J, Bano G, Poullis A. Gastrointestinal symptoms in acromegaly: A case control study. World J Gastrointest Pharmacol Ther 2020; 11(2): 17-24
- URL: https://www.wjgnet.com/2150-5349/full/v11/i2/17.htm
- DOI: https://dx.doi.org/10.4292/wjgpt.v11.i2.17